Literature DB >> 29045532

Stevens-Johnson syndrome during nivolumab treatment of NSCLC.

M Salati1, M Pifferi2, C Baldessari1, F Bertolini1, C Tomasello1, S Cascinu1, F Barbieri1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29045532     DOI： 10.1093/annonc/mdx640

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  11 in total

1.  Steven-Johnson Syndrome: A Rare but Serious Adverse Event of Nivolumab Use in a Patient With Metastatic Gastric Adenocarcinoma.

Authors:  Eltaib Saad; Pabitra Adhikari; Drashti Antala; Ahmed Abdulrahman; Valiko Begiashvili; Khalid Mohamed; Elrazi Ali; Qishou Zhang
Journal:  J Med Cases       Date:  2022-09-28

Review 2.  Cutaneous Adverse Events Associated with Immune Checkpoint Inhibitors: A Review Article.

Authors:  Chieh-Hsun Chen; Hsin-Su Yu; Sebastian Yu
Journal:  Curr Oncol       Date:  2022-04-18       Impact factor: 3.109

Review 3.  Management of immune checkpoint inhibitor-related dermatologic adverse events.

Authors:  Xiaoyan Si; Chunxia He; Li Zhang; Xiaowei Liu; Yue Li; Hanping Wang; Xiaoxiao Guo; Jiaxin Zhou; Lian Duan; Mengzhao Wang; Li Zhang
Journal:  Thorac Cancer       Date:  2019-12-09       Impact factor: 3.500

4.  Inactivation of the PD-1-Dependent Immunoregulation in Mice Exacerbates Contact Hypersensitivity Resembling Immune-Related Adverse Events.

Authors:  Matin Dokht Ashoori; Kensuke Suzuki; Yosuke Tokumaru; Naoko Ikuta; Masaki Tajima; Tasuku Honjo; Akio Ohta
Journal:  Front Immunol       Date:  2021-01-27       Impact factor: 7.561

5.  Cutaneous immune-related adverse events among Taiwanese cancer patients receiving immune checkpoint inhibitors link to a survival benefit.

Authors:  Yung-Tsu Cho; Yi-Tsz Lin; Che-Wen Yang; Chia-Yu Chu
Journal:  Sci Rep       Date:  2022-04-29       Impact factor: 4.996

Review 6.  An Overview of Clinical Oncology and Impact on Oral Health.

Authors:  Jack A Harris; Giulia Ottaviani; Nathaniel S Treister; Glenn J Hanna
Journal:  Front Oral Health       Date:  2022-04-25

Review 7.  Hypersensitivity reactions to monoclonal antibodies: Classification and treatment approach (Review).

Authors:  Irena Pintea; Carina Petricau; Dinu Dumitrascu; Adriana Muntean; Daniel Constantin Branisteanu; Daciana Elena Branisteanu; Diana Deleanu
Journal:  Exp Ther Med       Date:  2021-07-03       Impact factor: 2.447

Review 8.  A Case of Nivolumab-Induced Bullous Pemphigoid: Review of Dermatologic Toxicity Associated with Programmed Cell Death Protein-1/Programmed Death Ligand-1 Inhibitors and Recommendations for Diagnosis and Management.

Authors:  Adriana T Lopez; Larisa Geskin
Journal:  Oncologist       Date:  2018-07-17

Review 9.  [Management of Dermatologic Toxicities Related to Immune Checkpoint Inhibitors].

Authors:  Xiaoyan Si; Chunxia He; Li Zhang; Xiaowei Liu; Yue Li; Hanping Wang; Xiaoxiao Guo; Jiaxin Zhou; Lian Duan; Li Zhang
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2019-10-20

10.  Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events.

Authors:  Julie R Brahmer; Hamzah Abu-Sbeih; Paolo Antonio Ascierto; Jill Brufsky; Laura C Cappelli; Frank B Cortazar; David E Gerber; Lamya Hamad; Eric Hansen; Douglas B Johnson; Mario E Lacouture; Gregory A Masters; Jarushka Naidoo; Michele Nanni; Miguel-Angel Perales; Igor Puzanov; Bianca D Santomasso; Satish P Shanbhag; Rajeev Sharma; Dimitra Skondra; Jeffrey A Sosman; Michelle Turner; Marc S Ernstoff
Journal:  J Immunother Cancer       Date:  2021-06       Impact factor: 13.751
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.